Premium
Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti‐epidermal growth factor receptor monoclonal antibodies: A meta‐analysis
Author(s) -
Xu Qi,
Xu An Tao,
Zhu Ming Ming,
Tong Jin Lu,
Xu Xi Tao,
Ran Zhi Hua
Publication year - 2013
Publication title -
journal of digestive diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 51
eISSN - 1751-2980
pISSN - 1751-2972
DOI - 10.1111/1751-2980.12063
Subject(s) - medicine , colorectal cancer , monoclonal antibody , epidermal growth factor receptor , monoclonal , oncology , mutation , epidermal growth factor , receptor , antibody , cancer research , cancer , immunology , gene , genetics , biology
Objective This study aimed to evaluate the predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer ( mCRC ) treated with anti‐epidermal growth factor receptor ( EGFR ) monoclonal antibodies (MoAbs). Methods Computer searches of the literature on BRAF mutation in mCRC patients were performed. Studies with objective response rate ( ORR ) to anti‐ EGFR MoAbs and/or overall survival ( OS ) and progression‐free survival ( PFS ) with different BRAF gene expression in mCRC patients were eligible. Results A total of 19 studies including 2875 patients was enrolled in the meta‐analysis. BRAF mutation was detected in 246 patients. The ORR was 18.4% (40/217) in mutant BRAF group and 41.7% (831/1993) in the wild‐type BRAF group. The overall risk ratio ( RR ) for the ORR of BRAF mutation patients compared with wild‐type BRAF patients was 0.58 (95% confidence intervals [ CI ] 0.35–0.94, P = 0.027). The median PFS of patients with BRAF mutation was significantly shorter than that of patients with wild‐type BRAF (hazard ratio [ HR ] 2.98, 95% CI 2.07–4.27, P < 0.001) and the median OS of patients with BRAF mutation was also significantly shorter than that of those with wild‐type BRAF ( HR 2.85, 95% CI 2.31–3.52, P < 0.001). Conclusion BRAF mutation is associated with poor response to anti‐ EGFR MoAbs and it is an adverse prognostic biomarker of the survival of patients with mCRC .